Q4 2021 13F Holders as of 31 Dec 2021
-
Type / Class
-
Equity / Common shares, Euro 0.12 nominal value per share
-
Shares outstanding
-
26,019,256
-
Total 13F shares
-
8,054,131
-
Share change
-
-163,698
-
Total reported value
-
$44,296,000
-
Price per share
-
$5.50
-
Number of holders
-
18
-
Value change
-
-$912,124
-
Number of buys
-
4
-
Number of sells
-
8
Institutional Holders of LAVA Therapeutics NV - Common shares, Euro 0.12 nominal value per share (LVTX) as of Q4 2021
As of 31 Dec 2021 LAVA Therapeutics NV - Common shares, Euro 0.12 nominal value per share (LVTX) had 18 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of 8,054,131 shares of stock of the company.
Largest 10 holders included Novo Holdings A/S, Redmile Group, LLC, Nicholas Investment Partners, LP, Nantahala Capital Management, LLC, AXA S.A., Artal Group S.A., DAFNA Capital Management LLC, SPHERA FUNDS MANAGEMENT LTD., Alpha Wave Global, LP, and Point72 Asset Management, L.P..
This table shows 18 institutional shareholders of the security as of 31 Dec 2021.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.